Free Genetic Testing Program
…test kit screens for BRCA and other mutations linked to hereditary ovarian and gynecologic cancers. Answer a few questions to determine if you qualify for a free testing kit. Do…
Search Results
OCRA Awards $7 Million in Research Grants for 2023
…Cancer Center, “Synthetic Lethality of the Protexin and BRCA Complexes in Ovarian Cancer” Brooke Howitt, MD, Stanford University, “Identifying the Cell of Origin for High Grade Serous Carcinoma” Xiaowen Hu,…
USPSTF Recommends Against Routine Screening For Ovarian Cancer
…at higher risk for developing ovarian cancer. Risk factors include family history of ovarian cancer, mutations in genes known to increase risk (BRCA1 and BRCA2), diagnosis of pre-menopausal breast cancer…
Q&A with Melinda Yates, Ph.D.
…research findings into advances that can improve health outcomes in women at high-risk for ovarian cancer due to inherited mutations in the BRCA1 and BRCA2 genes. Dr. Yates has received…
Study Finds Genetic Testing Underutilized Among Ovarian Cancer Patients
…While the numbers of those tested increased over time, and especially accelerated after the approval of PARP inhibitors for BRCA1 and BRCA2 mutated chemotherapy-refractory ovarian cancer in December 2014, the…
June 2016 ASCO Highlights
…intravenous chemotherapy and stating that BRCA1/2 patients could benefit from the use of IP. All agreed that there are unresolved issues regarding the use of IP chemotherapy and much work…
New Genetic Markers for Ovarian Cancer Discovered
…were identified for breast (n = 1) and ovarian (n = 2) cancers in BRCA1 mutation carriers and for breast cancer (n = 1) in BRCA2 mutation carriers. An epigenetic…
Highlights from the June 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
…114, and 172) resulted in longer PFS using intraperitoneal compared to intravenous chemotherapy and stating that BRCA1/2 patients could benefit from the use of IP. All agreed that there are…
Niraparib Receives FDA Approval as First-Line Maintenance Therapy for Advanced Ovarian Cancer
…regardless of BRCA mutation status. Niraparib was first approved by the FDA for treatment of recurrent ovarian cancer in 2017. This most recent approval means ovarian cancer patients do not…
Press Release: Cancer Groups Praise Coverage of Genetic Counseling and Testing Under Affordable Care Act, Urge Coverage of Other Vital Services
…and ovarian cancer risk in women with a family history of cancer. Breast and ovarian cancers have been linked to mutations in the BRCA1 and BRCA2 genes. The Ovarian Cancer…
OCRA Featured in Fortune on Surgery That Reduces Ovarian Cancer Risk
…does not affect hormone levels or ovarian function. Those with genetic risk—such as a BRCA1 or BRCA2 mutation—may want to consider salpingectomy even without a separate planned surgery. Explore OCRA’s…
OCRFA Research Finds New Genetic Variants Linked to Ovarian Cancer
A study published in Nature Genetics has identified nine new susceptibility loci, or disease-associated alleles, for different epithelial ovarian cancer (EOC) histotypes and three susceptibility loci within BRCA1 and 2…